Compare · ACGN vs ARGX
ACGN vs ARGX
Side-by-side comparison of Aceragen Inc. (ACGN) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACGN and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX carries a market cap of $52.52B.
- ARGX has hit the wire 6 times in the past 4 weeks while ACGN has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 0 for ACGN).
- Company
- Aceragen Inc.
- argenx SE
- Price
- -
- -
- Market cap
- -
- $52.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ACGN
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Axogen shares are trading lower after the company reported worse-than-expected Q2 revenue results and maintained FY23 revenue guidance.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Why Aceragen (ACGN) Stock Is Down 30% Today
- Aceragen shares are trading lower after the company announced it will delist from the Nasdaq.
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Aceragen, Inc. To Delist from The Nasdaq Stock Market
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE